Difference between revisions of "Part:BBa K1722010"
(2 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
<html> | <html> | ||
− | <img style="width:10%" src="https://static.igem.org/mediawiki/2015/ | + | <img style="width:10%" src="https://static.igem.org/mediawiki/2015/2/2c/SZU_China_igem_logo.png"/ |
</html> | </html> | ||
{| style="color:black" cellpadding="5" cellspacing="1" border="3" align="right" | {| style="color:black" cellpadding="5" cellspacing="1" border="3" align="right" | ||
Line 16: | Line 16: | ||
|- | |- | ||
|'''Backbone''' | |'''Backbone''' | ||
− | |pSB1C3 | + | |[https://parts.igem.org/Help:Plasmid_Backbones pSB1C3] |
|- | |- | ||
|'''Submitted by''' | |'''Submitted by''' | ||
Line 58: | Line 58: | ||
</html> | </html> | ||
+ | |||
+ | We also constructed two plasmids and three plasmids system with GFP as their reporter gene. These systems were transfected into T24, a kind of bladder cancer cell. The working efficiency of our orthogonal system can be detected by comparing the luminescence intensity of green fluorescent of each groups. Two plasmids system is composed of hUPll-AckRS-GFP(amber mutated) and hTERT-tRNA. And the construction members of three plasmids system include hUPll-AckRS, hTERT-tRNA and SV40-GFP(amber mutated). Each system is divided into two groups: one have Ack in the medium and another one do not have Ack. Adding a positive control group, which is constructed by hUPll-GFP(wild-type), we have five groups of bladder cancer cells in total. Luminescent intensity results are shown in '''Fig. 4'''. | ||
+ | <html> | ||
+ | |||
+ | <figure style="text-align: center"><img style="width:60%" src="https://static.igem.org/mediawiki/2015/f/f7/HTERT_GFP.png"/><figcaption style="text-align:center"><b>Figure 4.</b> Green fluorescent intensity. <figcaption style="text-align:center">(A: Positive Control Group B: Two Plasmids-no Ack Group C: Two Plasmids-with Ack Group D: Three Plasmids-no Ack Group E: Three Plasmids-with Ack Group </figcaption></figure> | ||
+ | |||
+ | </html> | ||
+ | |||
+ | As we can see, no cell in Two Plasmids-no Ack Group and Three Plasmids-no Ack Group produce green fluorescent light. In Two Plasmids-with Ack Group and Three Plasmids-with Ack Group, however, is full of luminescent cells. From this result, we can tell our orthogonal system work efficiently. | ||
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here |
Latest revision as of 14:22, 17 September 2015
hTERT+tRNA Composite | |
---|---|
Function | Produce aa-tRNA |
Use in | Cancer cells |
RFC standard | RFC 10 |
Backbone | pSB1C3 |
Submitted by | [http://2015.igem.org/Team:SZU_China SZU_China 2015] |
hTERT+tRNA Composite
hTERT+tRNA, the device that we constructed this year, will perform its function with two other devices hUPll+AckRS(BBa_K1722007) and SV40+Rlu(BBa_K1722012).
Targeted therapy has become the fastest growing subject in research on cancer treatment. Telomerase, which serves as the tumor marker, is activated in most malignancy while it's negatively expressed in normal cells. Because of the high expression of human telomerase reverse transcriptase(hTERT) gene in telomerase positive cancer cells, researchers construct plasmids with hTERT promoter and effector gene to target at cancer cells and kill them.[1] It has been proved that hTERT can regulate the activation and expression of telomerase in transcription level. Research shows that hTERT promoter is rich in GC but lack of TATA box or CAAT box. It's also methylated and deacetylated in different level.
We construct hTERT promoter and tRNA in the same plasmid to produce tRNA. In the unnatural amino acid orthogonal system that we are constructing, hUPll promoter and hTERT promoter can recognise bladder specific RNA polymerase and tumor specific RNA polymerase, respectively. Only when the two promoters are activated simultanuously can both AckRS and tRNA be produced. Our unnatural amino acid orthogonal system consists of three devices(plasmids).
(1)hUPll+AckRS(BBa_K1722007): hUPll is a bladder-cell specific promoter. when it's activated, AckRS, a tRNA synthetase, will be produced.
(2)hTERT+tRNA(BBa_K1722010)/ shTERT+tRNA(BBa_K1722011): hTERT and shTERT are cancer-cell specific promoters. tRNA can be expressed out when the promoter is activated.
(3)SV40+Rluc(BBa_K1722012): SV40 is a widely used strong promoter. Rluc is a reporter that can produce RLUC which is a kind of luciferase.
There is an amber stop codon UAG in the sequence of Rluc. The tRNA that is produced from the second plasmid has CUA as its anticodon, which can pair with the stop codon of the mRNA chain of Rluc. AckRS can achieve the attachment of Ack, the unnatural amino acid, and the tRNA. In this way, when all the three promoters are activated inside bladder cancer cell, Ack can be charged to the specific tRNA and then the anticodon of tRNA can pair with the stop codon on the mRNA chain of Rluc. In natural condition, this Rluc gene cannot be fully expressed because of the amber stop codon. However, with our orthogonal system, it can be produced and detected.
hTERT is 454bp in length. Fig. 1 shows the DNA sequence of hTERT is successfully amplified by PCR from psi-Check2 vector. From this electrophoretogram, we can see the brightness of hTERT PCR product is rather high compared with DNA Marker, which indicates that the PCR product of hTERT is in a high concerntration.
We then performed single digest(EcoRI) and double digest(EcoRI & PstI) to identify our pSB1C3-hTERT-tRNA plasmid.(Fig. 2) From the eletrophoretogram, we have two electrophoresis strips at about 562bp and 2070bp, which are exactly the length of hTERT+tRNA and pSB1C3, respectively in Track 2 and a strip at about 2632bp in Track 3. From this enzyme cutting result, we could make sure the Gene sequence of hTERT+tRNA succeeded in being constructed into pSB1C3 vector.
The three plasmids that we've constructed were inserted into three lines of cells(HFC, Hela and 5637). HFC is short for Human Fiber Cells, which is a kind of normal cell in human bladder. Hela and 5637 are cervical cancer cell line and bladder cancer cell line, respectively. We set two groups in each cell lines, one have Ack, an unnatural amino acid, in the culture medium, and another do not have it. The luminescence intensity of 5637 with Ack in the medium is much higher than other groups, which indicates that the specificity of the two promoters are high enough and our orthogonal system is working.(Fig. 3)
We also constructed two plasmids and three plasmids system with GFP as their reporter gene. These systems were transfected into T24, a kind of bladder cancer cell. The working efficiency of our orthogonal system can be detected by comparing the luminescence intensity of green fluorescent of each groups. Two plasmids system is composed of hUPll-AckRS-GFP(amber mutated) and hTERT-tRNA. And the construction members of three plasmids system include hUPll-AckRS, hTERT-tRNA and SV40-GFP(amber mutated). Each system is divided into two groups: one have Ack in the medium and another one do not have Ack. Adding a positive control group, which is constructed by hUPll-GFP(wild-type), we have five groups of bladder cancer cells in total. Luminescent intensity results are shown in Fig. 4.
As we can see, no cell in Two Plasmids-no Ack Group and Three Plasmids-no Ack Group produce green fluorescent light. In Two Plasmids-with Ack Group and Three Plasmids-with Ack Group, however, is full of luminescent cells. From this result, we can tell our orthogonal system work efficiently.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Design Notes
Both hTERT promoter and tRNA are achieved from Shenzhen Second People's Hospital. We designed primers and amplified the gene sequences from psi-Check2 vector. Using 3A Assembly method, we constructed hTERT and tRNA in pSB1C3.
Source
Both hTERT promoter and tRNA are achieved from Shenzhen Second People's Hospital.
References
[1] Liu Y. Research Progress in Targeting Human Telomerase Reverse Transcriptase (hTERT) Promoter in Cancer Gene Therapy, Journal of Oncology, 15(3): 150-152